Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma (Q38751090)

6 September 2017

title

Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma (English)

1 reference

6 September 2017

1 reference

Cady Ploessl

1

1 reference

6 September 2017

Alice Pan

series ordinal

2

1 reference

6 September 2017

Kathryn T Maples

series ordinal

3

1 reference

6 September 2017

Denise K Lowe

series ordinal

4

1 reference

6 September 2017

language of work or name

English

0 references

publication date

25 February 2016

1 reference

Annals of Pharmacotherapy

6 September 2017

published in

1 reference

6 September 2017

volume

50

1 reference

6 September 2017

issue

5

1 reference

6 September 2017

page(s)

416-422

1 reference

Advances in Risk Classification and Treatment Strategies for Neuroblastoma

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1060028016632013

Additional Therapies to Improve Metastatic Response to Induction Therapy in Children With High-risk Neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028016632013

Long-term follow-up of children with high-risk neuroblastoma: the ENSG5 trial experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028016632013

Chronic health conditions in adult survivors of childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028016632013

Clinical ascertainment of health outcomes among adults treated for childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028016632013

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028016632013

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028016632013

Disialoganglioside directed immunotherapy of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028016632013

Anti-GD2 antibody therapy for GD2-expressing tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028016632013

Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028016632013

Airway and lung remodelling in chronic pulmonary obstructive disease: a role for muscarinic receptor antagonists?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028016632013

Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028016632013

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028016632013

Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028016632013

Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028016632013

21 January 2018

Identifiers

DOI

10.1177/1060028016632013

1 reference

6 September 2017

1 reference